AbbVie is expected to report second-quarter neuroscience revenues of $3.09 billion, a 15% year-over-year increase, when it announces results on July 31. The consensus estimate reflects continued momentum from key products including Botox Therapeutic, Vraylar, Ubrelvy, and Qulipta. Vyalev, which generated $201 million in the first quarter, is projected to reach $238 million in the second quarter and remains on track for blockbuster status this year. AbbVie faces competition in the neuroscience space from Biogen and Johnson & Johnson, with Biogen focusing on newer therapies like Leqembi and Zurzuvae, and J&J anchored by Spravato and Invega Sustenna. AbbVie shares have underperformed the industry year to date and currently trade at a forward price-to-earnings ratio of 16.02, below the industry average of 18.23.
AbbVie IncExpected 15% YoY growth in neuroscience revenue driven by key products.
Biogen IncMentioned as competitor with newer therapies like Leqembi and Zurzuvae.
Johnson & JohnsonMentioned as competitor anchored by Spravato and Invega Sustenna.